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Abstract
P-cadherin is frequently over-expressed in high-grade invasive
breast carcinomas and has been reported to be an enhancer of
migration and invasion of breast cancer cells, being correlated with
tumour aggressiveness. In addition, expression of P-cadherin is
well established as an indicator of poor prognosis in human breast
cancer, which has stimulated our interest in studying its role in this
setting. This review describes the most important findings on
P-cadherin expression and function in normal mammary tissue and
breast cancer cells, emphasizing that further research is required
to elucidate the role played by this protein in human mammary
tumours.
Introduction
Classical cadherins, such as E-cadherin, N-cadherin and P-
cadherin, are the best characterized subgroup of adhesion
proteins; they mediate calcium-dependent cell-cell bonds
when they are localized to the adherens-type junctions. These
cellular structures are found near to the apical surface of
polarized epithelial cells, where E-cadherin (or epithelial
cadherin) is the typical adhesion molecule present. However,
other cadherins are found in similar structures in various cell
types [1].
P-cadherin (or placental cadherin) was the third classical
cadherin to be identified and characterized in the mouse
visceral endoderm cell line PSA5-E [2,3], and it is this protein
that constitutes the main subject of this review. Despite its
name, P-cadherin is not expressed in human placenta [4]; its
name results from the fact that this molecule was originally
observed to be highly expressed in mouse placenta
throughout pregnancy [2,4].
The gene encoding P-cadherin (CDH3) is far less well
characterized than is CDH1 (the gene that encodes
E-cadherin), although they share 66% homology. It also maps
to chromosome 16q22.1, a region that contains a cluster of
several cadherin genes, just 32 kilobases upstream of the
gene encoding human E-cadherin [5,6]. Mutations in the
CDH3 gene have been reported to be responsible for
congenital hypotrichosis associated with juvenile macular
dystrophy, which is a rare autosomal-recessive disorder
characterized by abnormal growth of scalp hair, followed by
progressive macular retinal degeneration that leads to early
blindness [7].
The mature P-cadherin glycoprotein has a molecular weight
of 118 kDa, and its structure is similar to that of classical
cadherins but different from those of E-cadherin and N-
cadherin in terms of immunological specificity and molecular
mass [2]. It is comprised of three distinct domains
(extracellular, transmembrane and cytoplasmic) and it mainly,
but not exclusively, promotes homotypic interactions
(between cadherins of the same type) [1,2]. The amino-
terminal domain is essential for the creation of lateral dimmers
that act together in a zipper-like structure between neigh-
bouring cells (Figure 1) [8].
The function and strength of P-cadherin mediated adhesion
probably depends on its dynamic association with a group of
cytoplasmic molecules, called catenins. These molecules
serve to link the cadherin cytoplasmic tail to the actin
cytoskeleton and facilitate clustering into the junctional
structure, forming cadherin-catenin complexes (Figure 1)
[8,9]. This tail comprises two main domains: the catenin-
binding domain (CBD), which is known to be essential for
cadherin function, and the juxtamembrane domain (JMD),
which has been suggested to play a critical role in allowing
cells to relocate [1]. The α, β, γ and p120 catenins are the
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documented interaction partners [10]. β-Catenin (and also γ-
catenin) is a signalling molecule that is involved in tissue
patterning, and it is regulated by the CBD, tyrosine
phosphorylation and transcriptional factors [11]. P120-
catenin interacts directly with the JMD and is also regulated
by tyrosine kinases, modulating cadherin intracellular
trafficking, stability, adhesive capacity and cell motility [12-
14]. The α-catenin links the cadherin-catenin junctional
complex to the actin cytoskeleton [11].
In 1989, Shimoyama and coworkers [4] showed that NIH3T3
cells transfected with human P-cadherin cDNA expressed the
functional cadherin molecule, which was able to mediate cell-
cell adhesion. The amino-terminal domain is essential in
determining the specificity of this molecule [15]. Although
both E-cadherin and P-cadherin are found in areas of cell-cell
contact, the relative ease with which P-cadherin can be
extracted from cells, using a non-ionic detergent, demon-
strated weaker anchorage of this protein to the actin
cytoskeleton when compared with E-cadherin. Also, the
binding corresponds to less permanent cell-cell interactions
than those attributed to epithelial cadherin [16].
P-cadherin is transiently expressed in various tissues during
development [17,18] and its permanent expression is limited
to adult epithelial tissues, at cell-cell boundaries [19]. Unlike
E-cadherin, which is broadly distributed in all epithelial
tissues, P-cadherin exhibits a singular pattern of expression,
co-localizing partially with E-cadherin and being restricted to
the basal proliferative cell layer of the majority of stratified
epithelia. Some authors have even suggested that its
expression could be correlated with cell undifferentiation and
proliferation in these type of tissues, as well as with the
connection or segregation of cell layers, as found for other
cadherins [2,19-21].
The adherens-type junctions play an important role in cell
sorting during embryogenesis and in the maintenance of
specific organ and adult tissue architecture [22,23]. They are
also essential in intracellular signalling mechanisms [11,24],
which regulate cell polarity, differentiation, growth and
migration [25]. Because of their importance in normal
development, disorders involving dysfunction of classical
cadherins/catenins are related to various disease states,
including cancer [10,26,27].
P-cadherin in embryogenesis, mammary
development and normal breast tissue
The formation of tissues and organs during embryogenesis
requires the coordination of cellular processes, including cell
polarization, aggregation, segregation and migration. Each of
these processes depends on the expression of specific
adhesion proteins. The various cadherin family members are
expressed in specific spatiotemporal patterns during the
development of an embryo, which is consistent with the view
that cadherins play roles in regulation of morphogenesis and
in tissue formation.
It has become clear that cadherins constitute a major cellular
adhesion/recognition system that confers upon cells the
ability to sort from one another during embryogenesis, in
order to form specific tissues. For example, cells transfected
with E-cadherin segregate from cells transfected with
P-cadherin when these two populations are mixed together in
an aggregation assay [28]. In addition, Steinberg and
Takeichi [29] showed that cells expressing different levels of
Figure 1
Schematic representation of the classical cadherin-catenin complex. Classical cadherins (blue), which mediate calcium-dependent (red)
intercellular adhesion, are composed by an extracellular domain, a transmembrane domain and a cytoplasmic domain. This last domain comprises a
juxtamembrane domain (JMD), which binds p120-catenin (violet), and a catenin-binding domain (CBD), which binds β-catenin (green), which in
turns binds α-catenin (orange). Both α-catenin, α-actinin (grey) and vinculin (pink) establish a direct link between the cadherin-catenin complex and
the actin cytoskeleton (yellow).Page 3 of 12
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the same cadherin also sort from one another. Based on
these experiments, the general idea is that when a group of
cells separate from an existing cell layer, the segregating cells
express a qualitatively or quantitatively altered set of cadherin
family members. This might mean that cells are able to turn off
some cadherin genes or turn on others during their lives [30].
P-cadherin was first described in developing mouse embryos,
specifically in the extra-embryonic ectoderm and in the
visceral endoderm at the egg cylinder stage, but not in the
embryonic ectoderm. Later, it is expressed in various tissues,
with the mouse placenta and uterine decidua exhibiting the
most abundant expression of this protein [2]. Based on these
findings, Nose and Takeichi [2] proposed that differential
expression of P-cadherin on both sides of embryonic and
maternal tissues of the early placenta could play a role in
implantation  and morphogenesis of mice embryos, by
providing cells with heterogeneous adhesive specificities. The
expression of P-cadherin is transient in several mouse tissues
during development, and its permanent expression becomes
limited to the epidermis, the mesothelium and the corneal
endothelium [2]. In the adult mouse, some tissues such as
skin, intestine, heart and lung only weakly express this protein.
Brain and liver are essentially negative for P-cadherin.
In both mouse and human embryos, during the histogenesis of
the surface epidermis and hair follicles, P-cadherin is
expressed exclusively in the proliferating region of these tissues
[20], segregating hair follicle keratinocytes into functionally
distinct subpopulations [31]. Based on these findings, P-
cadherin has been described as being crucial for orderly
progression of terminal differentiation of the epidermis [21].
Mammary ducts and the highly mitotic terminal end buds from
which they are derived consist of two layers of ectodermally
derived epithelium, forming a ‘tube within a tube’ structure.
Immunostaining shows abundant E-cadherin on the lateral
membranes of end bud body cells and ductal luminal cells,
but no P-cadherin expression. The basally located ‘cap’ cells,
which represent the growth point for ductal development of
the mammary gland and their differentiated descendants, the
ductal myoepithelial cells, exhibit strong P-cadherin expres-
sion [32]. Because functional blocking cadherin antibodies
induce disruption of these layers, previous data indicate that
spatially selective expression of E-cadherin and P-cadherin is
required for mammary tissue integrity [33]. Interestingly, virgin
P-cadherin null female mice exhibit precocious differentiation
of the mammary gland, and develop hyperplasia and
dysplasia with age. These results indicate that P-cadherin
mediated adhesion or signals derived from its cell-cell
interactions are indeed important determinants of mammary
gland growth control and in the maintenance of an
undifferentiated state during a specific period of time [34].
In normal adult nonlactating breast tissue, spatially selective
expression of E-cadherin and P-cadherin appears to be
important for mammary gland differentiation [35]. E-cadherin
is expressed by both luminal and myoepithelial cells, whereas
P-cadherin is restricted to myoepithelial cells [35,36]. How-
ever, during late pregnancy and lactation in humans and dogs
P-cadherin is not found at cell-cell borders, as expected for
an adhesion molecule, but rather appears to be secreted by
epithelial cells [37,38]. Additionally, an 80 kDa soluble
fragment of P-cadherin is frequently found in body fluids,
including milk from the lactating breast, although its biological
role in this context is still unknown [37,39,40].
P-cadherin role in breast carcinogenesis
Because of the importance of cadherins in cell recognition,
adhesion, sorting and signalling, their disruptive function of
P-cadherin has significant implications in disease states,
including cancer. P-cadherin has been detected as altered in
various human tumours, but its role in the carcinogenic
process remains unclear because it behaves differently
depending on the cancer cell model studied.
For example, P-cadherin behaves like a tumour suppressor
gene in malignant melanoma, in which there is a progressive
loss of normal E-cadherin and P-cadherin expression from
melanocytes, followed by an increase in N-cadherin expres-
sion [41,42]. This allows cells to invade and migrate,
releasing them from the control of keratinocytes and enabling
interaction with fibroblasts and vascular endothelial cells [42].
Therefore, in this model P-cadherin functions as a pro-
adhesive and anti-invasive molecule, inhibiting invasion and
metastasis [43].
On the other hand, and particularly in breast cancer, P-
cadherin is able to enhance cell invasion and tumour
aggressiveness, and constitutes a factor that indicates a
poorer prognosis for the patient [44]. Thus, our current
understanding of the role played by P-cadherin in carcino-
genesis and progression of breast cancer continues to direct
research toward its putative value in diagnosis, prognosis and
treatment of this heterogeneous disease.
P-cadherin as a marker in the differential diagnosis and
prognostication of breast lesions
In human breast carcinomas, which represent a hetero-
geneous group of tumours that are diverse in behaviour,
outcome and response to therapy, P-cadherin has been
found to be aberrantly expressed in a small subgroup of
carcinomas. Based on microarray technology, which allows
linkage between different expression profiles and clinical
outcome, this molecule essentially is expressed in those
breast lesions termed basal-like carcinomas [45], which are
negative for oestrogen receptor (ER), progesterone
receptor (PgR) and HER2 (triple negative phenotype). These
carcinomas carry poor prognosis, and there is still no specific
or effective therapy for them [46]. However, the use of
particular markers that are expressed only in basal cells (or
myoepithelial cells) of the mammary gland have led to a
Available online http://breast-cancer-research.com/content/9/5/214recently developed strategy to improve the diagnosis, prog-
nosis and treatment in these tumours. This has heightened
interest in conducting detailed studies of P-cadherin in this
type of cancer.
Aberrant expression of P-cadherin is detected in about 30%
of known mammary cancer cell lines, which motivated its
study in large series of breast carcinomas. In an early study
reported in 1993 [36], P-cadherin was identified in only one
out of 25 (4%) of invasive breast carcinomas (Table 1). In a
subsequent study [35] its expression was observed in about
20% (9/45) of infiltrating ductal carcinomas and was related
to reduced expression of E-cadherin and high tumour
histological grade (Table 1) [35]. With the development of
commercial P-cadherin monoclonal antibodies, it was
demonstrated that P-cadherin is expressed in almost half of
invasive ductal carcinomas of the breast (around 30% to
50%; Table 1) but it is infrequent in the lobular type, in which
the main oncogenic event is loss of E-cadherin expression
[47]. Most importantly, P-cadherin expression was reported
to be strongly associated with poor patient survival and was
even considered to be a valuable independent prognostic
factor in breast carcinogenesis in one of the studies
performed (Table 1) [35,44,47-52]. Although a fragment of
P-cadherin was detected in serum, which could be important
for tumour diagnosis, its level was considerably lower and
was not correlated with the presence of P-cadherin positive
breast cancer [39].
In contrast with these findings, Madhavan and coworkers
[53] found that 71% of cases were positive for P-cadherin in
a series of invasive breast carcinomas, which they considered
to be a good independent prognostic factor because it was
associated with better patient survival (Table 1). These
contradictory findings probably resulted from the choice of
polyclonal antibody to detect P-cadherin, which cross-reacts
with other cadherins.
In 2002 our group demonstrated, for the first time, aberrant
P-cadherin expression in a subset of ductal carcinomas in
situ, demonstrating a predominant membranous staining
(Figure 2) [49]. Curiously, most of these cases were positive
for E-cadherin, and regardless of the adopted histological
classification P-cadherin expression was significantly
associated with high histological grade and decreased cell
polarity, as well as with nuclear pleomorphism. In contrast, all
of the lobular carcinomas in situ that we studied were
negative for P-cadherin.
Using the same approach in a series of invasive breast
carcinomas, we found 31% of tumour samples to exhibit
moderate to intense P-cadherin membrane immunostaining,
usually associated with cytoplasmic expression and some-
times focally distributed. Once again, P-cadherin expression
was strongly correlated with high histological grade and with
decreased patient survival over short-term follow up (Table 1).
The probabilities of disease-free and overall survival were
significantly lower for patients with P-cadherin positive
tumours. Half of the studied cases were negative for E-
cadherin, indicating a clear decrease in membranous staining
in neoplastic epithelial cells. P-cadherin expression was
independent of tumour size, lymph node metastasis and
angiogenesis, as described in other studies (Table 1).
Although no significant correlation was observed with histo-
logical type, the majority of positive P-cadherin tumours were
invasive ductal carcinomas and metaplastic and medullary
carcinomas (Figure 2) [44].
We and others have also reported that P-cadherin expression
is inversely related to hormonal receptor content (the majority
of the cases are negative for ER and PgR) [35,44,47-
52,54,55] and directly related to the expression of the
epithelial growth factor receptor [51], HER2, p53 expression
[44], high proliferation rates (MIB-1) and mitotic index and
decreased cell differentiation, which are biological conditions
with strong associations with poor survival of breast cancer
patients [35,44,47,48] (Table 1).
Based on these findings, P-cadherin expression is considered
a good indicator of poor prognosis in breast cancer patients.
However, we and others have also found that this protein,
together with p63 and cytokeratin (CK)5, can identify invasive
basal-like carcinomas by immunohistochemistry [56,57] and
is one of the most useful adjunctive markers for distinguishing
the precursor basal-like lesions of ductal carcinoma in situ
[58]. Interestingly, it was demonstrated that most hereditary
BRCA1 mutated breast carcinomas are characterized by
absence of ER and PgR, and expression of basal
(myoepithelial) markers such as CK5/6 or P-cadherin [59,60].
P-cadherin expression can be used to identify those patients
who are likely to carry a BRCA1 germline mutation, thus
indicating who should be screened first in families with a high
incidence of breast and ovarian cancer [57,59-62]. Very
recently, Turner and coworkers [63] demonstrated that
sporadic basal-like cancers exhibit a dysfunctional BRCA1
pathway, either by BRCA1 promoter methylation or by
downregulation of its transcripts because of upregulation of
the ID4-negative BRCA1 regulator [63]. Based on this, it has
been suggested that BRCA1 can transcriptionally regulate
the basal phenotype, repressing genes such as those
encoding CK5, CK17, or even P-cadherin. In breast cancer
cells with a BRCA1 mutation, this repression does not occur
and these genes are codified and expressed [64].
The aberrant expression of P-cadherin by breast cancer cells
has been explained by several hypotheses, although none has
yet been proved valid. Palacios and coworkers [35] suggested
that its expression could indicate a proliferative ability acquired
by tumour cells with high mitotic index, to respond to E-
cadherin downregulation and to maintain cancer cell nests.
However, although this protein is essentially present in
proliferative cells, no significant changes in proliferation rates
Breast Cancer Research    Vol 9 No 5 Paredes et al.
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.were seen when breast cancer cells were transfected with P-
cadherin cDNA (data not reported), indicating that it is not
directly involved in cell division. Additionally, we also identified
P-cadherin expression in E-cadherin positive cells, showing
that expressions of these two cadherins are not mutually
exclusive, as was previously proposed [54].
An alternative to this theory is that P-cadherin could be a
member of an oncofetal protein family, because it is highly
expressed in embryogenesis and neoplasias, and is weakly
and focally expressed in adult tissues [35]. Nevertheless,
there is not yet any evidence to confirm the validity of this
hypothesis either.
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Figure 2
Schematic representation of P-cadherin positive and negative breast cancer histological types. In normal breast, P-cadherin is only expressed by
myoepithelial cells and not by luminal epithelial cells. In the low-grade arm of breast carcinomas, the majority of lesions are negative for P-cadherin
expression, such as invasive lobular carcinomas (ILC), tubular carcinomas, and well differentiated ductal carcinoma in situ (DCIS) and invasive
ductal carcinomas (IDC). In the other arm, high-grade lesions are frequently positive for this cadherin, including the medullary carcinomas, a subset
of poor-differentiated DCIS and IDC, and the metaplastic carcinomas, which represent a clear subtype of basal-like carcinomas.More recently it was suggested that the expression of
P-cadherin by tumour cells could be related to a histogenetic
origin in cap cells or acquisition of a phenotype with
characteristics similar to this type of stem cell [47,48]. The
higher migration capacity of cap cells, the absence of ER
expression, and the ability to differentiate into myoepithelial
cells suggest that they could be responsible for the
development of P-cadherin positive breast cancer cells
[47,65,66]. The observation that metaplastic and medullary
breast carcinomas are consistently immunoreactive for
P-cadherin (Figure 2) [48,67] supports a myoepithelial/basal-
like transcriptomic programme for these lesions [67-72]. Han
and coworkers [67] reported P-cadherin expression in all
cases of sarcomatoid metaplastic breast carcinoma and
carcinosarcomas, which is supported by our own findings.
Sapino and colleagues [73], using rat mammary tumour-
derived cell lines with clones that have epithelial and myo-
epithelial/basal phenotypes, demonstrated that myoepithelial
clone derived tumours usually grow in a sarcomatous or
carcinosarcomatous pattern, whereas epithelial derived
tumours exhibited a carcinomatous pattern. One of our
studies has yielded new evidence for a myoepithelial/basal-
like transcriptomic programme for this heterogeneous group
of neoplasms, because all cases were positive for at least
one of the basal/myoepithelial markers studied, including P-
cadherin [68]. We also showed that P-cadherin expression in
canine malignant tumours was significantly related to spindle
cell carcinoma, carcinosarcoma and osteosarcoma. In these
lesions, both carcinomatous and sarcomatous components of
carcinosarcoma expressed P-cadherin [74,75]. These
findings support the hypothesis that there is a common
histogenesis for both elements from stem cells, with the
capacity for divergent differentiation, as suggested by several
studies on human and canine mammary tumours [76], but
more data are needed to clarify this issue.
Although these specific types of P-cadherin positive
carcinomas indeed appear to have a myoepithelial/basal-like
transcriptomic programme, this explanation is unlikely to
account for the percentage of P-cadherin expressing ductal
carcinomas. In these specific lesions, it is easier to accept
that some molecular mechanism would lead to activation of
P-cadherin expression. However, expression of human
P-cadherin has been demonstrated in mammary epithelial
cells under control of the mouse mammary tumour virus
promoter, and the effect on mammary gland behaviour was
studied [32]. P-cadherin was detected in most, but not all,
luminal epithelial cells and was appropriately localized to cell-
cell borders. Despite the robust and widespread expression
of an inappropriate cadherin in epithelial cells, however, no
effect was observed on mammary gland morphogenesis,
architecture, lactation, or involution. Because previous
published work had revealed that women whose tumours
expressed P-cadherin had poorer prognosis than did women
whose tumours lacked P-cadherin, Radice and coworkers
[32] considered that P-cadherin expression might somehow
increase the aggressive behaviour of mammary tumour cells.
To test this possibility, they opted to induce mammary
tumours in P-cadherin transgenic mice by mating them with a
transgenic mouse model that develops mammary tumours in
response to an oncogene, namely the mouse mammary
tumour virus/neu mouse. However, the results were
inconclusive because all of the detected tumours failed to
express P-cadherin, despite the fact that the normal
epithelium was positive [32]. It therefore remains possible
that if P-cadherin is mis-expressed following epithelial
transformation, then it can alter the behaviour of the tumour
cells and play a causal role in contributing to the poor survival
of women with P-cadherin positive breast cancers. Based on
this, it would be more appropriate to study the biological
impact of induced P-cadherin expression in a model in which
mice develop basal-like cancers, such as that recently
described by McCarthy and coworkers [77]. They presented
a conditional mouse model of BRCA1 deficiency, which
leads to basal-like tumour formation.
CDH3 promoter methylation regulates P-cadherin
expression in breast cancer cells
Deciphering the mechanism that controls P-cadherin expres-
sion would be helpful in designing new therapies for
P-cadherin positive breast tumours. It is known that
expression of an inappropriate cadherin can result from
stimulation by growth factors and hormones in the tumour
environment, as well as from changes in the promoter regions
of cadherin encoding genes [78]. For example, changes in
DNA methylation or acetylation in tumour cells might trigger
improper cadherin expression, as is well established for the
E-cadherin gene [78].
The sequence of the upstream 5’ region of the P-cadherin
gene exhibits structural similarities to the 5’ region of the
E-cadherin gene [79]: absence of a TATA box, presence of a
CAAT box, two putative AP2-binding motifs, and a CG-rich
region containing several Sp1-binding elements, which are
characteristic of CpG islands. However, no homologous
sequence to the palindromic sequence E-pal found on the
E-cadherin promoter (for repressor elements) has been
found in the 5’ region of the P-cadherin gene [80]. Some
years ago, Jarrard and coworkers [79] found that cytosine
methylation of this region occurs in P-cadherin negative
prostate cancer cell lines but not in cell lines expressing this
protein. However, in vivo, a lack of expression in 12 prostate
cancer specimens was not associated with methylation of
the P-cadherin promoter. Recently, we found a significant
correlation between P-cadherin expression and
hypomethylation of a specific region of the CDH3 promoter,
suggesting an important regulatory role for cytosine
methylation in the aberrant expression of P-cadherin in
breast cancer [44]. Interestingly, using laser microdissection,
we were able to study normal P-cadherin negative
epithelial/luminal cells, which we found to be consistently
methylated in this promoter region.
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expression in breast cancer cells
It is becoming increasingly clear that all of the information
received from cell-cell, cell-matrix, and growth factor and
hormone signalling determines ultimate cellular phenotype
and behaviour during normal embryonic development and
during abnormal processes, such as tumourigenesis. There-
fore, signalling pathways that are involved in the regulation of
cadherin-mediated adhesion are thought to underlie the
dynamics of the adhesive interactions between cells [81,82].
Thus far, little is known about the signalling pathways that
may be involved in regulation of P-cadherin expression in
breast cancer cells.
One of our aims has been to characterize which intracellular
pathways could induce P-cadherin expression in breast
carcinomas. Based on the fact that P-cadherin positive
tumours are essentially ER negative, we opted to study the
link between ER signalling and the regulation of P-cadherin
expression in breast cancer cell lines. Thus, it was
postulated that P-cadherin expression in breast carcinomas
could be related to a phenotype that is insensitive to
circulating hormones, as has been suggested by Gamallo
and coworkers [48] in invasive ductal breast carcinomas
and by Soler and colleagues [83] in prostate cancer.
Interestingly, we found that abnormal P-cadherin expression
results from a lack of ER-α signalling [54], because
treatment of breast cancer cells with the pure anti-
oestrogen ICI 182,780 can induce a twofold to threefold
increase in protein and mRNA levels. This effect was time
and dose dependent, and could be counteracted by 17β-
oestradiol (E2) [84]. Taken together, these findings suggest
that the lack of ER-α signalling is responsible for the
increase in P-cadherin, categorizing CDH3 as an
oestrogen-repressed gene and pointing to E2 as a key
regulator of this cadherin.
Finally, it remained to be determined whether induction of the
P-cadherin gene is a direct effect of anti-oestrogens or
requires prior induction of other genes. In one study [54]
blocking protein synthesis in cells with cycloheximide, to
which induction of primary target proteins should not be
sensitive, potently inhibited P-cadherin upregulation by ICI
182,780. This finding was consistent with a requirement for
newly synthesized proteins, probably induced by the anti-
oestrogen, before CDH3 activation.
We have demonstrated that treatment of MCF-7/AZ breast
cancer cells with ICI 182,780 leads to decreased cell-cell
adhesion and promotion of invasion in vitro [54]. This is in
accordance with the finding that E2 [85], and even the
unliganded receptor [86], may decrease in vitro invasiveness
and motility of breast cancer cells, suggesting that some
oestrogen-regulated genes negatively control invasion.
Because this control is lost in cells treated with high
concentrations of ICI 182,780, which upregulate P-cadherin,
the effect of the latter has been further investigated in in vitro
aggregation and invasion of cells retrovirally transduced with
P-cadherin [54].
Role of P-cadherin expression in invasion and motility
of breast cancer cells
Cancer cells can invade into neighbouring tissues, surviving
in these ectopic sites and giving rise to metastases in
secondary organs, when the normal regulation of a complex
network of signalling pathways that are involved in prolifer-
ation and migration is lost [81]. Although aberrant epithelial
P-cadherin expression is associated with a proliferative and
undifferentiated cell phenotype related to ulceration and
neoplastic transformation, the relative functional role played
by P-cadherin in breast cancer cell invasion and motility is not
fully elucidated [87]. This is due in part to results obtained
with transgenic mice expressing high levels of P-cadherin in
the normal mammary epithelium that did not develop tumours,
even when neu oncogene induced mammary tumours were
produced, giving rise to consistently P-cadherin negative
lesions [32].
Loss of cell polarity is one of the indicators of cell
undifferentiation, and adhesion molecules normally provide
the spatial structure for the establishment of a polarized
epithelium [88,89]. The progression from normal polarized
epithelia to a malignant invasive phenotype is attributed in
part to loss of E-cadherin, with a resulting increase in cell
motility. However, some studies have suggested that other
mechanisms should be able to induce loss of cell polarity
without loss of epithelial cadherin expression [90]. Based on
our previous findings, we suggested that aberrant P-cadherin
expression can also be responsible for loss of cell polarity
because it mediates weaker and unstable cell-cell contacts,
which are easily broken and reformed [44,49,54] and are
unable to maintain differentiated epithelial cells. We therefore
opted to study the role played by P-cadherin in breast cancer
cell aggregation and invasion.
Surprisingly, we found that P-cadherin retroviral transduction
of MCF-7/AZ breast cancer cells (E-cadherin positive) did
not produce striking changes in cell-cell aggregation, which
suggested that P-cadherin does not shift the balance of
aggregation established by the endogenous cadherin in this
system [54]. By contrast, such a balance could well be
changed for invasion, because we found that P-cadherin
transduction was enough for induction of invasion. Because
the pro-invasive action of P-cadherin is unlikely to be the
result of alterations in cell-cell adhesion, we presumed that
the pro-invasive activity of P-cadherin was due to changes in
cytoplasmic signalling pathways, as was described for
E-cadherin. Wong and Gumbiner [91] attributed the anti-
invasive activity of wild-type E-cadherin to its interaction with
β-catenin, because an E-cadherin mutant, retaining the CBD
but with a point mutation that abolishes p120-catenin
binding, was still able to suppress invasion.
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maintenance of the JMD is crucial for induction of invasion,
irrespective of the CBD [54]. We showed that P-cadherin is
unable to induce invasion when its JMD is not present or
when the p120-catenin binding domain is mutated, sugges-
ting a role for this catenin in the induction by P-cadherin of
cell invasion [54].
The JMD binding to p120-catenin has been already
implicated in the stable maintenance of endogenous cad-
herins [13,92]. Ireton and colleagues [92] showed that
restoration of p120-catenin in a colon carcinoma cell line
resulted in E-cadherin stabilization and rescue of its function,
either directly or indirectly by preventing other proteins from
hampering E-cadherin. Based on this finding, we suggested
that a related mechanism could account for the induction of
invasion by P-cadherin, in which destabilization of anti-
invasive cadherin/catenin complexes would result from
competition for the available p120-catenin. Alternatively,
P-cadherin could generate a specific pro-invasive signal via
its JMD. In this hypothesis, JMD binding of p120-catenin, or
other proteins, to P-cadherin must differ from the binding to
E-cadherin or N-cadherin in terms of strength, conformation,
or recruitment of other members of the complex. This, in turn,
may result in the activation of pathways that overcome the
suppressive signals mediated by the endogenous cadherins.
Recently, in accordance with our findings, it was shown that
the differences between E-cadherin and N-cadherin in
recruitment of various phosphorylated isoforms of p120-
catenin to the membrane might be responsible for the inability
of N-cadherin to replace E-cadherin as a suppressor of
invasion in pancreatic carcinoma cells [93].
Although the JMD of cadherins is highly conserved, it is
important to note that its function is dependent on cell type. It
may both positively and negatively regulate cadherin activity
[94-98]. Except for the demonstrated induction of invasion,
no regulatory functions have been described for the
P-cadherin JMD. Although binding of proteins to the JMD of
P-cadherin has been documented only for p120-catenin [99],
we cannot exclude the possibility that its disruption intro-
duces conformational changes or uncouples the interaction
of other proteins that could be responsible for the observed
effects. Striking examples of this were shown for E-cadherin,
in which functional differences were noted between larger
and minimal deletions of the JMD, with even minimal changes
disrupting binding of multiple molecules [100].
Data on the role played by p120-catenin in normal and
cancer cells are also conflicting. Positive and negative
regulation of cell-cell adhesion and motility possibly reflect
differences in cell type, cadherins, p120-catenin isoforms,
and shuttling between cadherin-bound and cytoplasmic pools
[101]. When over-expressed in the cytoplasm, p120-catenin
may regulate the actin cytoskeleton and cell motility, through
Rho GTPase activity [102]. Similarly, in our experiments
differences in binding strength between E-cadherin, N-cad-
herin and P-cadherin bound p120-catenin may influence its
effect on the activity of the Rho GTPases, possibly making
the cells more likely to invade. Alternatively, the panel of
molecules recruited by p120-catenin may differ depending on
the cadherin it is bound to.
Recently, Taniuchi and coworkers [103] reported that
P-cadherin is also over-expressed in the majority of pancreatic
ductal adenocarcinomas and that this over-expression is
strongly associated with cytoplasmic accumulation of p120-
catenin, activating Rho GTPases and promoting cell motility.
Recently, we also found that P-cadherin can induce migration
and motility of breast cancer cells, bringing the majority of
p120-catenin to the cytoplasm and changing the actin
phenotype of these cells (lamelipodia and filopodia forma-
tion). These cells can even produce a greater amount of
matrix metalloproteases, which explains their capacity to
invade through collagen and matrigel (data not published).
In summary, our work establishes a novel role for JMD and
distinguishes P-cadherin mediated invasion from invasion
induced, for example, by N-cadherin, which depends on a
physical interaction with fibroblast growth factor receptor
[53,104]. Moreover, although the P-cadherin JMD differs in
only few amino acids from the corresponding E-cadherin
domain, it exerts an opposing function; whereas E-cadherin
JMD suppresses motility [105], P-cadherin JMD plays a role
in cell invasion. To elucidate why such related domains can
have opposite functions, it will be crucial to identify new
interaction partners or to study whether the interaction of
known partner molecules differs between these cadherins.
Conclusion
Several reports have already indicated that P-cadherin
expression in mammary carcinomas is associated with poor
prognosis in patients [45,48,49]. However, the effect and
regulation of this protein in breast tumour cell biology, and
consequently in the progression of this disease, remain
unknown. The experiments and results that are discussed in
the present review provide four novel insights into the role
played by P-cadherin in breast carcinogenesis. Specifically,
they show that its expression is associated with more
aggressive tumours and with shorter patient survival; it
reflects the methylation status of its promoter gene; it is
regulated by the ER-α signalling pathway; and it is involved in
the ability of cells to invade through artificial extracellular
matrices, such as collagen type I and matrigel.
It remains to be determined whether P-cadherin is an
independent predictor of outcome and a true determinant of
the biology of breast cancers, or is a mere surrogate marker
for a more global basal-like profile.
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